PP2A Activators for Imatinib-Resistant Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for BCR/ABL-mediated leukemias, such as chronic myelogenous leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph1-ALL), face challenges with resistance development and relapse, particularly due to the T315I mutation, which is resistant to existing therapies like imatinib and dasatinib.
Innovation Solution
Administering PP2A phosphatase activating compounds, including protamine sulfate, rolipram, forskolin, and their derivatives, to activate protein phosphatase 2A (PP2A) and downregulate SET expression, thereby inhibiting BCR/ABL kinase activity and expression, even in imatinib-resistant cases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If imatinib and dasatinib are used to treat BCR/ABL-mediated leukemias, then leukemia treatment effectiveness is improved, but resistance development occurs particularly due to T315I mutation
Solution Approach 1:
The patent changes the therapeutic parameter from BCR/ABL kinase inhibition to PP2A phosphatase activation. By administering PP2A activating compounds, the treatment mechanism shifts from blocking oncogenic kinase activity to restoring phosphatase activity, thereby overcoming resistance to conventional kinase inhibitors including T315I mutation.
Solution Approach 2:
The patent introduces PP2A activating compounds as an intermediary mechanism. These compounds activate PP2A phosphatase, which then dephosphorylates and inactivates BCR/ABL kinase, providing an indirect but effective way to target the oncogenic pathway while bypassing resistance to direct kinase inhibitors.
2Adaptability or versatility
If PP2A activating compounds are administered to overcome resistance, then treatment versatility is improved, but new therapeutic mechanisms must be developed
Solution Approach 1:
The patent leverages the cell's own PP2A phosphatase system to combat leukemia. By administering activating compounds, the treatment restores the body's natural phosphatase activity that opposes BCR/ABL kinase, allowing the cellular machinery to fight the disease rather than relying on external kinase inhibition.
3Reliability
If SET expression is downregulated to activate PP2A, then BCR/ABL kinase activity is inhibited, but new pathways must be targeted
Solution Approach 1:
The patent employs preliminary action by downregulating SET expression before or concurrent with PP2A activation. By reducing SET levels, the inhibition on PP2A is removed in advance, allowing PP2A to become active and subsequently inhibit BCR/ABL kinase activity more effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Restoration of PP2A activity leads to growth suppression, enhanced apoptosis, impaired clonogenic potential, and decreased leukemogenesis, effectively targeting both wild-type and T315I BCR/ABL leukemias, offering a new therapeutic strategy for CML and Ph1-ALL.
Implementation Method 1
Administering PP2A phosphatase activating compounds, including protamine sulfate, rolipram, forskolin, and their derivatives, to activate protein phosphatase 2A (PP2A) and downregulate SET expression
Implementation Method 2
Forskolin, a diterpene, is a potent activator of adenylate cyclase that has been used extensively to increase intracellular cAMP levels and to elicit cAMP-dependent physiological responses
Data Source
AI summary
The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph′-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.